Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Trevena

Trevena, Inc. (Nasdaq: TRVN), headquartered in Chesterbrook, PA, is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

Trevena
Finance

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024November 8, 2024 - by Timothy Alexander

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) released its financial results for the third quarter ending September 30, 2024, revealing significant corporate changes as the company navigates ongoing financial challenges. …

Trevena, Inc. Navigates Financial Challenges and Strategic Changes Read More

Trevena
Public Companies

Trevena, Inc. Faces Delisting from Nasdaq

October 5, 2024October 5, 2024 - by Timothy Alexander

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced that its common stock is set to be delisted from The Nasdaq Stock Market LLC following a decision by the Nasdaq Hearings Panel …

Trevena, Inc. Faces Delisting from Nasdaq Read More
Trevena
Equities

Trevena Announces Reverse Stock Split to Regain Nasdaq Compliance

August 11, 2024August 10, 2024 - by Timothy Alexander

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) has announced a reverse stock split of its common stock at a ratio of 1-for-25. The split will take effect at 12:01 a.m. …

Trevena Announces Reverse Stock Split to Regain Nasdaq Compliance Read More

Trevena
Finance

Navigating Trevena’s Potential: Buy, Sell, or Hold?

August 10, 2024August 9, 2024 - by Timothy Alexander

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) has announced its financial results for the second quarter ended June 30, 2024, along with key operational updates.

Navigating Trevena’s Potential: Buy, Sell, or Hold? Read More
Trevena
Finance

Trevena Secures New Financing Amendment with R-Bridge Healthcare Fund

July 8, 2024July 8, 2024 - by Timothy Alexander

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) has announced a significant amendment to its existing royalty-based financing agreement with R-Bridge Healthcare Fund, L.P. This amendment brings both immediate and potential …

Trevena Secures New Financing Amendment with R-Bridge Healthcare Fund Read More

Trending News

  • New Chester County Program Aims to Reach Isolated Veterans

  • West Chester Film Festival Celebrates 20 Years With Global Lineup and Local Pride

  • Lancaster Welcomes Baseball Back With Free Fan Fest This Saturday

  • Emergency Funds Offer Breathing Room When It Matters

  • Philadelphia Man Sentenced to 210 Months for Home Invasion Robberies

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Vet ambassadors

New Chester County Program Aims to Reach Isolated Veterans

15 minutes ago22 hours ago

Court News

Philadelphia Man Sentenced to 210 Months for Home Invasion Robberies

12 hours ago23 hours ago

Police

Calls for Service, Drug Arrests, and DUI Cases Mark February Activity

13 hours ago23 hours ago

Copyright © 2026 MyChesCo.